Eli Lilly and Company & Sun Pharma
4 shared events · Importance 3 · Last updated Jul 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
Eli Lilly and Company: Eli Lilly was among the earlier drugmakers that agreed to MFN pricing, contributing to the administration's drug pricing push.
Sun Pharma: Sun Pharma extended MFN pricing to United States — Medicaid and future launches, gaining a two-year tariff reprieve. The deal supports its planned $11.75 billion acquisition of Organon & Co., though shares dipped about 1%.
Aug 18, 2026 · 37 articles
Regulatory
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in India's obesity-drug market with Mounjaro; the approval may intensify competition.
Sun Pharma: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
Business
Eli Lilly and Company: Eli Lilly's Olumiant is a competitor JAK inhibitor for alopecia areata; positive bempikibart data may increase competition.
Sun Pharma: Sun Pharma's Leqselvi is a competitor JAK inhibitor; potential competitive pressure from bempikibart.
Jul 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Eli Lilly and Company and Sun Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard